Huayan Robotics raises HK$1.58bn in Hong Kong debut after retail book is covered 5,059 times
Chinese collaborative robot maker Guangdong Huayan Robotics began trading in Hong Kong under code 1021 on 30 March 2026 after pricing its H shares at HK$17.00 and raising HK$1,579.34 million gross. The retail tranche was subscribed 5,059.38 times, while preliminary 2025 results showed revenue up 24.6% to RMB386.9 million and a net loss of about RMB29.9 million.
Guangdong Huayan Robotics began trading on the Main Board of the Hong Kong Stock Exchange on 30 March 2026 under stock code 1021, three weeks after Estun Automation opened its own H-share line. The collaborative robot maker, based in Foshan and Shenzhen, priced its offering at HK$17.00 per H share, according to the final offer price and allotment results announcement it filed with HKEX on 27 March.
The company sold 92,902,600 H shares after exercising its Offer Size Adjustment Option in full, raising gross proceeds of HK$1,579.34 million. Listing expenses were estimated at HK$101.17 million, leaving net proceeds of HK$1,478.18 million. At the offer price the company was valued at HK$9,241 million on 543,597,580 shares in issue, the filing showed.
Demand from Hong Kong retail investors was extreme. The public tranche drew 227,070 valid applications and was subscribed 5,059.38 times, with 66,270 applicants receiving shares. The international tranche was covered 16.65 times. Nine cornerstone investors took 45,265,600 shares between them, led by HHLR Advisors with 13,802,400 shares and GF Fund with 13,802,200, followed by Morgan Stanley & Co. International with 4,600,800 and Samson Group with 2,941,000.
The aftermarket was cooler than the order book. In an announcement dated 24 April 2026, Huayan said the over-allotment option had been partially exercised for 13,469,000 H shares at HK$17.00, adding net proceeds of about HK$220.69 million, and that the stabilising manager had bought 466,200 H shares in the market at HK$16.80 during the stabilisation period, which ended that day. Issued share capital rose to 557,066,580 shares.
- Huayan Robotics
- 1021
- 2026-03-30
- 17
- 92,902,600
- 1579.34
- 5059.38
- 16.65
- Estun Automation
- 2715
- 2026-03-09
- 15.36
- 96,780,000
- 1486.54
- 19.67
- 3.34
- Geek+
- 2590
- 2025-07-09
- No data
- No data
- No data
- 133.62
- 30.17
- Dobot
- 2432
- 2024-12-23
- 18.8
- 40,000,000
- 752
- 9.25
- 2.64
Figures from each company's HKEX allotment results announcement or listing release; disclosed, not estimated. Huayan shares include full exercise of the Offer Size Adjustment Option and exclude over-allotment; Estun and Dobot exclude over-allotment. Geek+ pricing not taken from a primary page here and left blank.
As of Oct 1, 2026
Huayan builds collaborative arms under the Elfin family, including the Elfin-Pro with integrated AI vision and force control and the explosion-proof Elfin-Ex, alongside the heavier S Series, a seven-axis humanoid arm, the STAR mobile manipulator and its own motors, servo drives and joint modules. The prospectus dated 20 March says cobot shipments rose from 1,821 units in 2023 to 3,164 in 2024 and reached 3,364 in the first nine months of 2025, with heavy-payload S Series units climbing from 93 to 808 over the same span. In 2025 the company launched a modular drive motor designed for humanoid robots. Its customers are system integrators, distributors and end users in semiconductors, genetic sequencing, power batteries and consumer electronics.
Growth has been fast while profit has lagged. Revenue rose from RMB175.4 million in 2023 to RMB310.4 million in 2024, and preliminary figures in the prospectus put 2025 revenue at RMB386.9 million, up 24.6%. Gross margin widened from 28.6% in 2023 to 34.3% in 2024 and 37.6% in the first nine months of 2025. A net profit of RMB17.9 million in 2024 turned into a loss of about RMB29.9 million in 2025, which the company attributed to listing expenses, share-based payment and higher research spending. On an adjusted basis it reported a profit of RMB25.7 million.
- 2023
- 175.4
- 28.6
- 1.9
- 1821
- 26.5
- 2024
- 310.4
- 34.3
- 17.9
- 3164
- 50.2
- 9M 2025
- 280.9
- 37.6
- -15.6
- 3364
- 37.8
- FY 2025
- 386.9
- No data
- -29.9
- No data
- No data
From the HKEX prospectus dated 20 March 2026, including preliminary 2025 results in Appendix IIA. FY 2025 net figure is a loss of about RMB29.9 million; adjusted profit was RMB25.7 million. Blank = not disclosed for that period.
As of Oct 1, 2026
Overseas sales are the swing factor. Revenue from outside mainland China made up 26.5% of the total in 2023 and 50.2% in 2024, before falling back to 37.8% in the first nine months of 2025, prospectus data show. The company says it operates in Germany, the United States and Japan, and it cites Frost & Sullivan data ranking it the second-largest cobot company in China in 2024 with a 10.3% share and among the top five worldwide with 3.5%. The same consultant sized the global cobot market at RMB7.5 billion in 2024, up from RMB2.5 billion in 2020, and forecast RMB35.0 billion by 2029.
The listing adds Huayan to a growing group of Chinese robot makers quoted in Hong Kong. Dobot, the cobot specialist that listed under code 2432 in December 2024, raised HK$752.00 million gross at HK$18.80 with a retail book covered 9.25 times. Estun, the Nanjing industrial robot maker, raised HK$1,486.54 million at HK$15.36 and began trading on 9 March 2026 after retail cover of 19.67 times. Warehouse robot maker Geek+ drew retail cover of 133.62 times in July 2025. Domestic cobot rivals JAKA and Elite Robots remain private, and Teradyne's Universal Robots competes with all of them in export markets.
Huayan plans to spend 55% of net proceeds on research and development, 20% on global business development, 15% on production capacity and 10% on working capital, according to the prospectus. Chief executive Wang Guangneng controls 35.84% of the voting rights. Wang, Zhang Guoping and four partnership vehicles have locked up 159,742,800 H shares until 29 March 2027, the allotment announcement shows.
The open questions concern margin and mix. The statutory loss in 2025, the decline in the overseas share after 2024 and price competition among Chinese cobot vendors all bear on whether the gross margin gains of 2023 to 2025 can be turned into a reported profit. The interim report for the six months to 30 June 2026, due under HKEX rules by 31 August, is the first test as a listed company.
MEKAWIRE analysis
Huayan's order book shows that Hong Kong will pay for Chinese cobot volume, yet the 2025 statutory loss and stabilisation buying below the offer price show the aftermarket is pricing margin delivery rather than unit growth.
The evidence sits in the filings. Retail cover of 5,059.38 times dwarfed the 19.67 times Estun drew three weeks earlier and the 9.25 times Dobot drew in 2024, yet the stabilising manager still had to buy 466,200 shares at HK$16.80. Gross margin climbed to 37.6% in the first nine months of 2025 while the full year closed with a statutory loss of about RMB29.9 million against an adjusted profit of RMB25.7 million.
The strongest counter-argument is scale. Stabilisation purchases were small next to the 92,902,600 shares sold, and 13,469,000 of the 13,935,200 over-allotment shares were issued, about 96.7%, which means demand largely held at HK$17.00.
Bull case. Heavy-payload S Series volumes, which rose from 93 units in 2023 to 808 in nine months of 2025, keep lifting mix and margin, while in-house motors and joint modules give Huayan a second business supplying humanoid builders. With 55% of proceeds going into research, the company can stay ahead of domestic rivals on force control and vision.
Bear case. Chinese cobot pricing tightens further, the overseas share stays below the 50.2% reached in 2024, and share-based payment keeps statutory results in the red. In that scenario the HK$9,241 million listing valuation leans on a growth rate that slowed to 24.6% in 2025.
Signals to watch:
- 31 August 2026: interim results for the six months to 30 June, with gross margin against 37.6% and overseas share against 37.8%.
- Late March 2027: 2026 annual results and whether the statutory loss reverses.
- 29 March 2027: expiry of the lock-up on 159,742,800 H shares held by the controlling shareholders.
- 1021 (HKEX Main Board)
- Net loss of about RMB29.9 million; adjusted profit RMB25.7 million
- HK$17.00 per H share
- RMB386.9 million, up 24.6%
- 30 March 2026
- HK$1,579.34 million (92,902,600 H shares)
- 16.65 times subscribed
- No. 2, 10.3% share (Frost & Sullivan)
- 5,059.38 times subscribed
- HK$9,241 million
Why it matters
Huayan is the first pure collaborative robot maker to list in Hong Kong since Dobot in December 2024, and its 5,059.38 times retail cover is the clearest measure so far of how much Hong Kong retail money wants exposure to Chinese robotics hardware. It also arrived in the same month as Estun, giving investors two very different industrial robot stories to price side by side.
The deal matters for the private cobot makers behind it. JAKA and Elite Robots, both still unlisted, now have a public comparable with audited unit volumes, margins and an overseas revenue split, which will shape how their own investors and any future sponsors value them.
Rival analysis
Against Dobot, Huayan sells fewer units but leans harder into heavy-payload arms, where S Series volume rose from 93 units in 2023 to 808 in the first nine months of 2025. Against Estun, which spans large industrial robots and servo systems, Huayan is far smaller in revenue but carries a gross margin of 37.6% in nine months of 2025 and a narrower product focus.
The vertical integration claim is the competitive point to test. Huayan says it is the only Chinese cobot company with full-stack in-house hardware and software that also sells its core motion components independently. If that holds, the company competes with component suppliers as well as arm makers, and its 2025 humanoid drive motor gives it a route into humanoid supply chains that Dobot and Estun approach from different directions.
Valuation context
At HK$17.00 the company was valued at HK$9,241 million on 543,597,580 shares. Set against 2025 revenue of RMB386.9 million and a statutory loss of about RMB29.9 million, the valuation is a growth multiple, and it rests on the adjusted profit of RMB25.7 million and on gross margin expansion rather than on reported earnings.
The stabilising manager's purchases at HK$16.80, about 1.2% below the offer price, show the stock tested its issue price in the first weeks of trading. The near-full exercise of the over-allotment option, 13,469,000 of 13,935,200 shares, indicates that the dip was shallow and brief.
Supply-chain implications
Huayan designs and sells its own motors, servo drives and joint modules, which reduces dependence on outside servo suppliers and lets it offer components to other robot builders. The 2025 launch of a high power density, low vibration modular drive motor for humanoid robots extends that business toward humanoid makers.
Customer exposure runs through semiconductors, genetic sequencing, power batteries and consumer electronics, sectors where Chinese capital spending cycles are volatile. The overseas share of revenue, 50.2% in 2024 and 37.8% in nine months of 2025, ties results to demand in Germany, the United States and Japan, where tariffs and certification costs can shift quickly.
Signals to watch
The interim report due by 31 August 2026 will show whether gross margin holds near 37.6% and whether overseas revenue recovers toward the 2024 level. Unit volumes for the S Series and any disclosed humanoid component revenue will indicate whether the mix shift is continuing.
Further out, the 2026 annual results in late March 2027 and the expiry of the controlling shareholders' lock-up on 29 March 2027 are the two dated events most likely to move the shares. Any listing by JAKA or Elite Robots would also reset the comparable set.
Analyst view
Thesis: Huayan is a credible mid-sized cobot franchise with improving unit economics, priced on growth that has already begun to slow. Confidence: medium. The filings give audited volume, margin and geographic data, which supports the margin story, but the statutory loss, the drop in overseas share after 2024 and the absence of disclosed humanoid component revenue leave the growth case resting on management guidance rather than reported numbers.
We would upgrade confidence if the 2026 interim report shows statutory profit and an overseas share back above 40%, and downgrade it if gross margin falls below the 34.3% reached in 2024.
Questions you should be asking
How much of 2025 revenue came from motion components sold to third parties, and how much from humanoid related products? What drove the fall in overseas share from 50.2% in 2024 to 37.8% in the first nine months of 2025, and is it a timing effect or a loss of share abroad?
How large is the share-based payment charge expected to be in 2026 and 2027, and when does management expect statutory and adjusted profit to converge?